Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 113, Issue 7, Pages 996-1002
Publisher
Springer Nature
Online
2015-09-18
DOI
10.1038/bjc.2015.239
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer
- (2015) Arisa Nishimukai et al. Clinical Breast Cancer
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis
- (2013) F. E. Vera-Badillo et al. JNCI-Journal of the National Cancer Institute
- Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss
- (2013) Lisa Braun et al. MODERN PATHOLOGY
- Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma
- (2013) Fabien Reyal et al. PLoS One
- Prognostic comparison of the proliferation markers mitotic activity index, phosphohistone H3, Ki67, steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T 1-2 N 0 M 0 breast cancer
- (2013) Einar Gudlaugsson et al. POLISH JOURNAL OF PATHOLOGY
- Prognostic influence of BCL2 expression in breast cancer
- (2012) Ki-Tae Hwang et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
- (2012) Aleix Prat et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- Mise à jour des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France
- (2010) Frédérique Penault-Llorca et al. ANNALES DE PATHOLOGIE
- MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
- (2010) Mohammed A. Aleskandarany et al. BREAST CANCER RESEARCH AND TREATMENT
- Ki67 in breast cancer: prognostic and predictive potential
- (2010) Rinat Yerushalmi et al. LANCET ONCOLOGY
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients
- (2008) R. Stuart-Harris et al. BREAST
- Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
- (2008) Giuseppe Viale et al. JNCI-Journal of the National Cancer Institute
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now